Structural integrity vs. clinical utility: a critical review of bio-inductive scaffolds and autologous alternatives in rotator cuff repair.

Despite major advances in arthroscopic fixation constructs, healing after large-to-massive rotator cuff repair remains limited by a persistent biological bottleneck: failure to regenerate the native graded tendon-to-bone enthesis. Bio-inductive collagen scaffolds have emerged as a translational strategy intended to enhance host-cell infiltration, angiogenesis, collagen deposition, and tendon-like tissue formation rather than simply bridging a structural defect. This critical review synthesizes current Level I-IV evidence from 2004 to 2026 regarding the biological rationale, structural efficacy, clinical translation, safety, economic value, autologous alternatives, and future precision-medicine applications of bio-inductive augmentation in rotator cuff repair. High-level evidence increasingly supports the ability of scaffold-based augmentation to improve structural integrity, with recent meta-analyses and randomized trials demonstrating lower retear rates and improved imaging-based healing in selected cohorts. However, a recurring biology-function gap remains evident: statistically significant improvements in tendon integrity do not consistently translate into patient-perceived gains exceeding established thresholds such as the minimal clinically important difference, patient acceptable symptom state, or substantial clinical benefit. This discrepancy likely reflects the multifactorial nature of postoperative recovery, including tear chronicity, muscle fatty infiltration, tendon quality, patient age, rehabilitation, and baseline functional status. Importantly, value-based caution should not be interpreted as a recommendation against bio-inductive implants in small-to-medium tears. Recent guideline-supported and randomized evidence indicates that selected small-to-medium lesions, particularly those with intact rotator cable integrity, compromised tendon quality, biological risk factors, or high return-to-work demands, may benefit from bio-inductive strategies. Conversely, indiscriminate use in low-risk tears with favorable healing potential remains difficult to justify, especially in the context of implant cost and emerging autologous alternatives such as long head of the biceps and fascia lata grafts. Future progress will depend on phenotype-specific indications, cost-effectiveness analyses, AI-assisted risk prediction, and next-generation gradient or bioactive scaffolds capable of more closely reproducing the native enthesis. Overall, bio-inductive scaffolds should be viewed not as universally indicated implants, but as selective biological tools whose clinical and economic value depends on matching mechanism, patient phenotype, and surgical objective.